Wanbury Limited has informed the Exchange about Investor Presentation
N
ovember 2
22, 2025
BS d SE Limited J. Towers, PJ Da alal Street Mumbai – 40 M cript Code Sc
00 001. : 524212
De
ear Sir/Ma
adam,
ange of Ind ndra Kurla
dia Ltd, Complex,
National S Exchange Bandra (Ea Mumbai – Script Cod
Stock Excha Plaza, Ban ast), 400 051. de: WANB
BURY
Su Ob H1
ub.: Disclo bligations 1 FY26 Fin
osure unde s and Discl nancial Res
er Regulat losure Req sults
tion 30 of quirement
the Secur ts) Regulat
rities and tions, 2015
Exchange 5 - Investor
Board of rs Presenta
India (Lis ation on Q
sting Q2 &
Pl lease find a nd half yea an ww.wanbu ww
attached h ar ended 30 ury.com .
erewith co 0th Septem
opy of Inve mber, 2025 a
estors Pres and is also
sentation o o available
on Financia on the we
al Results f ebsite of th
for the qua he Compan
arter ny at
Th
his is for yo
our inform
mation and
record.
Th
hanking yo
ou.
Yo Fo
ours faithfu or Wanbur
ully, ry Ltd
Jit Co
tendra J. G ompany S
Gandhi ecretary
En
ncl.: a/a.
Towards Better Healthcare
Earnings Presentation Q2 & H1FY26 | November 2025
Wanbury Limited NSE: WANBURY | BSE: 524212 Bloomberg: WANB:IN
Inside this Presentation
Company Profile
Company Profile
Business Profile
Business Profile
Financial Profile
Financial Profile
Executive Summary
Corporate Journey
Successful Business Turnaround
Wanbury at a Glance
Business Streams
Board of Directors
Senior Leadership
R&D Capabilities
Environment, Health & Safety
04
05
06
07
08
09
10
11
12
API Business
API Business Strategically Curated Product Portfolio
World-Class Manufacturing Infrastructure
CAPEX Tracker
Developed Market Focused Business Profile
Regulatory Approvals
Manufacturing Capabilities
Strategy & Way Forward
Safety First Culture
14
15
16
17
18
19
20
21
Formulations Business
Formulations Business Re-Building Business
Brand Portfolio
Strategy & Way Forward
23
24
25
Q2 H1FY26 Earnings Update
Q2 & H1FY26 Earnings Update
Key Performance Indicators
5Y P&L Snapshot
5Y Balance Sheet Snapshot
5Y Cash Flow Snapshot
Capital Markets Overview
32
33
34
35
36
Performance Highlights
Business Verticals Performance
P&L Snapshot
Management Commentary
27
28
29
30
Investor Presentation | Wanbury Limited
2
Company Profile
Executive Summary
Corporate Journey
Successful Business Turnaround
Wanbury at a Glance
Business Streams
Board of Directors
Senior Leadership
R&D Capabilities
Environment, Health & Safety
04
05
06
07
08
09
10
11
12
0 1 / C O M P A N Y P R O F I L E
Executive Summary
Successful turnaround to growth momentum
Operational & financial turnaround over last 2 years, now transforming into growth momentum
Global market leaderships in key products
Globally significant market share in Metformin & Sertraline
Building new growth drivers in API business
Through launch of an Anaesthetic in Q4, and pipeline of 4 molecules commercialisation each year beginning next financial year
De-risked & robust balance sheet
Refinanced debt & healthy internal accruals i.e. moderate leverage ratio of ~2X Debt/EBITDA
Established global regulatory approvals
Levers for operating leverage & margin expansion
Through brownfield expansion, operational scale-up, and borrowing cost optimisation
Formulation growth story
Turnaround, envisaged break-even (in FY26), to rebuilding & scale-up (in FY27)
Investor Presentation | Wanbury Limited
4
0 1 / C O M P A N Y P R O F I L E
Corporate Journey
1990-2000
1990-2000 Foundation Early Strategic Acquisitions Foundation & Early Strategic Acquisitions
2000-2010
2000-2010 Venture into Developed Markets Corporate Consolidation Corporate Consolidation & Venture into Developed Markets
2010-2023
2010-2023 Challenges Business Turnaround Challenges & Business Turnaround
2024-Onwards
Transformation Growth
2024-Onwards Transformation & Growth
1990 Incorporated as Pearl Organics Pvt. Ltd.
2002 USFDA approval received for Patalganga plant
Underwent Corporate Debt Restructuring with Banks
2024 Scale up EBITDA to ₹73 crore
1992 Established 1st plant for manufacturing APIs
1995 Acquired Brij Chemicals’ plant at Patalganga (Maharashtra)
1995 Acquired Wander Limited → a subsidiary of Sandoz (Brand Formulation Business)
1996 Formed a strategic alliance with Wyckoff Chemicals (US) to market APIs in US
Investor Presentation | Wanbury Limited
2004 Wander Limited merged with Pearl Organics Limited → Renamed Wanbury Limited
2006 Acquired Doctor's Organic and Chemicals Limited (DOCL) with a multi-purpose USFDA-approved facility in Tanuku
2007 • DOCL merged with Wanbury
Limited
• Listing on NSE & BSE
• Acquired Cantabria Pharma
S.L. (Spain) - Present in ethical branded formulations in European market
2020 Deleveraged through strategic sale of brands to Cipla worth ₹87 crore
2021 Capital infusion of ₹50 crore through Preferential Issue
2023 • Raised ₹95 crore via NCD
from Neo AIF
• Settlement with all the
lenders
2025
• Modernised the facilities with an investment of ₹48 crore
• 6th successful USFDA inspection for Patalganga plant (zero 483 observations)
• Successful ANVISA audit
clearance for Tanuku plant
• Refinanced Neo AIF Debt at
lower interest rate
•
Achieved highest-ever Operational EBITDA of ₹80 crore
5
0 1 / C O M P A N Y P R O F I L E
Successful Business Turnaround
Financial Turnaround
Operational Turnaround
Debt reduction: ~75% reduction from peak- debt obligation of ~700 Crores, including corporate guarantee from Wanbury Limited to Wanbury Holding B.V. (Netherland) for foreign debt held by Netherlands subsidiary
Debt refinancing: Reduction in borrowing cost from 22.5% to 12.5% with effected from 1st March 2025, with scope for further reduction in coming years
Exited all high cost private financial agreements
Capacity ramp-up in key existing API products through de-bottlenecking: Metformin (25% increase in last 3 years) & Sertraline (20% increase in last 3 years)
Operational profitability: ~3X EBITDA scale-up between FY23-FY25, through de-bottlenecking projects & production scale- up, efficient procurement practises, technical savings, among others
Envisaged break-even profitability in Formulations business, delivered financial break-even in H1FY26
Investor Presentation | Wanbury Limited
6
0 1 / C O M P A N Y P R O F I L E
Wanbury at a Glance
6 products, 100% chronic portfolio API Portfolio
80%+ Export top line, with emphasis on developed markets
Regulatory Approvals
10+ brands, acute & semi-chronic Formulations Portfolio
2 USFDA approved API facilities with 386 KL cumulative reactor capacity
1,200+ Employee strength
37+ years Operating history
Dual revenue-stream
12%
88%
API
Formulation
Investor Presentation | Wanbury Limited
7
0 1 / C O M P A N Y P R O F I L E
Business Streams
API
API manufacturer building a niche, profitable & sustainable business (50%+ Gross contribution margins)
Diversified business stream across 6 products + additional launches in pipeline
Regulatory markets focused (EU, Brazil, US) mature & sustainable API business
₹530 Crore+ FY25 Revenue
₹282 Crore+ H1FY26 Revenue
Investor Presentation | Wanbury Limited
12%
₹600 Crore FY25 Revenue
88%
API
Formulations
Formulations
Rebuilding legacy brand formulations business in India
10+ active brands + additional launches in pipeline
Key therapeutic categories such as Anti cold & cough, Anti-infective, Anti- inflammatory, Supplements, Orthopaedic, among others
₹70 Crore+ FY25 Revenue
₹41 Crore+ H1FY26 Revenue
8
0 1 / C O M P A N Y P R O F I L E
Board of Directors
Mr. Mohan Kumar Rayana Promoter & Whole Time Director
Mr. K. Chandran Whole Time Director
Dr. Anupama Vaidya Non Executive Independent Woman Director
Mr. Mridul Mehta Non Executive Independent Director
Mr. Manoj Gursahani Non Executive Independent Director
Mr. Pallavur Sankar Das Non Executive Independent Director
25+ years of experience
30+ years of experience
30+ years of experience
30+ years of experience
35+ years of experience
35+ years of experience
He holds a Bachelor of Pharmacy from the University of Mumbai and brings over 30 years of diverse experience in the pharmaceutical industry. He has led the company’s growth since inception, overseeing strategic acquisitions and operational expansion.
He graduated with a Bachelor of Science from the University of Mumbai and has over 28 years of pharmaceutical sector experience. Mr. Chandran has played a key role in the company's strategic direction and has been associated with Wanbury for more than 25 years.
She holds a Bachelor’s degree in Computer Science from the University of Pune as well as an MBA specializing in Human Resource Development from Symbiosis Institute of Business Management, Pune. She brings a strong background in technology and HR development to the board.
Investor Presentation | Wanbury Limited
He holds a BE in Computer Science from Maharaja Sayajirao University Baroda and an MBA in Finance from the Indian Institute of Management (IIM), Bangalore. With more than 30 years of professional experience, Mr. Mehta specializes in business strategy, management consulting, investment banking, and finance.
He serves as the Executive Director of the Mumbai– Global Chamber and is Co-Founder of Vera Healthcare Technologies, an AI-driven platform for early screening and detection of Diabetic Retinopathy, Glaucoma, and Age-Related Macular Degeneration. He brings significant leadership experience from the healthcare and technology sectors.
He is an accomplished leader with more than 35 years of experience in the pharmaceutical industry. He has built and scaled businesses across India and other emerging markets. From 2014 to 2022, he was CEO and Director of Curatio Healthcare Private Limited, a domestic dermatology and cosmetic pharmaceutical company.
9
0 1 / C O M P A N Y P R O F I L E
Senior Leadership
Mr. Vinod Verma Chief Financial Officer
Mr. Prakash Venkatraman President – API Business
Mr. Rashesh Patel President – India Formulations Business
30+ years of experience
30+ years of experience
35+ years of experience
Mr. Vinod Verma is a qualified Chartered Accountant and Company Secretary with over 30 years of comprehensive experience in finance, taxation, audit, and management consultancy. He has held senior leadership roles across prominent organizations, including Escorts, Raymond, and JSW, contributing his expertise to diverse industry sectors.
Investor Presentation | Wanbury Limited
Mr. Prakash Venkatraman is a Chemical Engineer with a Master’s in Management Studies from Mumbai University, bringing over 30 years of leadership in API operations, business strategy, and P&L management. Before joining Wanbury, he led the API division at Shilpa Pharma Lifesciences, managed a $175 million global API portfolio at Sun Pharma, and scaled Jubilant Life Sciences’ API business to $105 million. His career also includes key roles at Wockhardt, Ranbaxy, and Kopran.
Mr. Rashesh Patel possesses more than 35 years of experience in pharmaceutical sales, marketing, and business transformation. He has served as Director at Kepler Healthcare and has held key leadership roles in renowned pharmaceutical companies such as Torrent, Emcure, Troikaa Pharmaceuticals, Astra ID, and Panacea Biotech. Notably, Mr. Patel drove the scale-up of Corona Remedies from three partially operational units to six pan-India divisions, significantly improving its market position from rank 107 to 36 (AWACS).
10
0 1 / C O M P A N Y P R O F I L E
R&D Capabilities
API R&D Center
Formulations R&D Center
Location Tanuku, Andhra Pradesh
DSIR and FDA (India) Recognized
Location Navi Mumbai, Maharashtra
DSIR and FDA (India) Recognized
R&D Competencies
Immediate Focus Areas:
R&D Competencies
•
•
•
•
•
•
New API development
Cost optimization for existing molecules
Troubleshooting plant problems
Analytical development
Process optimization
Backward integration development
•
•
•
•
Sertraline backward integration
Metformin yield improvement
New molecule commercialization's (4 annually)
Patented molecules process development (post-FY29 focus area)
Investor Presentation | Wanbury Limited
•
•
•
•
Cost optimizations
New product development
Process technology development
Development of Novel Platforms for Speciality Generics and Intellectual Property Rights (IPR)
R&D Capabilities
Process Optimization: Optimization of synthesis routes for enhanced yields & lowering costs
Impurity Control: Advanced analytical techniques aligned with ICH guidelines
Analytical Excellence: DSIR-approved R&D facility with validated methods
Green Chemistry: Integration of sustainable solvents, catalysis, and waste reduction efforts
Scale-Up Capability: Lab to commercial with FTE team, integrated QC lab
11
0 1 / C O M P A N Y P R O F I L E
Environment, Health & Safety
EHS at Wanbury •
Best-in-class standards: Committed to global EHS norms and strict regulatory compliance across all operations
•
•
Environmental focus: Zero liquid discharge (ZLD) plants, advanced Effluent Treatment Plants (ETP), and continual investment in energy efficiency
Sustainable energy: Upcoming 1.5 MW solar energy project at Satara, to meet 70% of Patalganga site’s energy requirements captively through renewable energy
•
•
Safety culture: Comprehensive training, systematic risk assessments (HAZOP), and robust emergency response systems at all sites
Community & workforce: Prioritizing safety, public health, and sustainability for employees and local communities
Sustainability & Environmental Stewardship
Workplace & Community Safety
Beyond Compliance: Creating a Lasting Impact
Global Compliance & Ethical Responsibility
Investor Presentation | Wanbury Limited
12
Business Profile: API
Strategically Curated Product Portfolio
World-Class Manufacturing Infrastructure
CAPEX Tracker
Developed Market Focused Business Profile
Regulatory Approvals
Manufacturing Capabilities
Strategy & Way Forward
Safety First Culture
14
15
16
17
18
19
20
21
0 2 / B U S I N ES S P R O F I L E: A P I
API: Strategically Curated Product Portfolio
Significant global market share in Top 3 products
Molecule
Metformin
Sertraline
Tramadol
Therapeutic Category
Antidiabetic
Antidepressant
Pain Management
Existing portfolio – 6 molecules
• Metformin - Antidiabetic • Sertraline - Antidepressant • Tramadol - Pain Management • Paroxetine - Antidepressant • Mefenamic acid - Anti-inflammatory • Diphenhydramine - Antihistamine
Upcoming portfolio – 1 molecule
• An Anaesthetic
(Planned commercialisation in Q4FY26)
• 4 new additions each year beginning FY27
Note - Market Size, Market Share data as per Clarivate & Company Estimates
Investor Presentation | Wanbury Limited
Global Market (MT)
Estimated Market Share
~75,000
~680
~550
~11%
~30%
~11%
API - Revenue & Share
API Sales Breakdown
600
500
400
300
200
100
0
Sales
Revenue Share
91%
90%
89%
88%
87%
356
443
435
513
530
FY21
FY22
FY23
FY24
FY25
Metformin
Sertraline
Tramadol Others
4%
6%
FY25
50%
40%
95%
90%
85%
80%
75%
70%
65%
60%
55%
50%
14
0 2 / B U S I N ES S P R O F I L E: A P I
API: World-Class Manufacturing Infrastructure
Site 1: Tanuku, Andhra Pradesh
Site 2: Patalganga, Maharashtra
400 KL Reactor Capacity
~70% Revenue Contribution
450+ Headcount
18 Acres Land Bank
Multi-Purpose Plant
Metformin, Sertraline, Tramadol, Paroxetine, MefenamicAcid, Diphenhydramine, (upcoming anaesthetic)
96 KL Reactor Capacity
Dedicated Plant Metformin, Metformin DC
~30% Revenue Contribution
250+ Headcount
Potential for future brownfield CAPEX
2.3 Acres Land Bank
Fully-occupied at present
Cumulative installed reactor capacity: 500 KL
Future reactor capacity potential at existing sites: 600 KL
Investor Presentation | OCTOBER 2025 Investor Presentation | Wanbury Limited
15
0 2 / B U S I N ES S P R O F I L E: A P I
API: CAPEX Tracker
1
FY24 (A)
Total – ₹7 Cr
2
FY25 (A)
Total – ₹48 Cr
• Replacements – ₹26 Cr
• Debottlenecking – ₹12 Cr
• Capacity Enhancement –
• Repairs & Maintenance –
₹10 Cr
₹ 0.5 Cr
• Debottlenecking – ₹6.5 Cr
4
FY27 (P)
Total – ₹63 Cr
• New Clean Room Facility –
₹12 Cr
• New Production Block + 2
Clean Rooms – ₹45 Cr
• New Storage Area – ₹6 Cr
3
FY26 (P)
Total – ₹64 Cr
• Replacements – ₹12 Cr
• Debottlenecking – ₹14 Cr
• Capacity Addition (New
Products) – ₹38 Cr
Investor Presentation | Wanbury Limited
16
0 2 / B U S I N ES S P R O F I L E: A P I
API: Developed Market Focused Business Profile
Focused on regulated markets
Exporting to 50+ countries
Exporting to 4+ continents
Total Revenue Mix
20%
80%
Exports
Domestic
Investor Presentation | Wanbury Limited
Map not to scale, only for illustration purpose.
17
0 2 / B U S I N ES S P R O F I L E: A P I
API: Regulatory Approvals
US-FDA
US – FDA Approval since 2000
Europe – EDQM Approval since 2007
Brazil – ANVISA Approval since 2024
South Korea – KFDA Approval since 2012
Mexico – COFEPRIS Approval since 2013
WHO GMP Approval since 2007
WHO GMP Approval since 2013
Last inspection 2024
Last inspection 2014
Last inspection 2024
Last inspection 2012
Last inspection 2013
Last inspection 2025
Last inspection 2025
DMF/CEP Filings with Global Regulatory Authorities
USA
Europe
Brazil
South Korea
Mexico
ROW
Total
Investor Presentation | Wanbury Limited
Approved
Under Review & Pending
22
8
1
3
-
30
64
-
1
5
-
-
-
6
Total
22
9
6
3
-
30
70
18
0 2 / B U S I N ES S P R O F I L E: A P I
API: Manufacturing Capabilities
Chemistry Capabilities
Reaction Capabilities
System Capabilities
• Azidation • Bromination • Cyanation • Chiral Chemistry • Optical Resolution • Demethylation • Grignard Reaction • Sodium Metal Reactions • Metal Hydride Reductions • Friedel-Crafts Reactions • Nitration • Reductions • Hydrogenation
• High Pressure Reactions • High Vacuum Distillations • Direct Compression (DC) Grade • Manufacturing Different Polymorphisms • Hydrated Molecules • Handling Hygroscopic Products
• Deployed SAP S4 HANA • Dedicated software for Sales &
Distribution functions
• Dedicated software for Fleet-on-Street • Dedicated platforms used for sourcing
& procurements
• Dedicated solutions for QC
management
Investor Presentation | Wanbury Limited
19
0 2 / B U S I N ES S P R O F I L E: A P I
API: Strategy & Way Forward
Way Forward
Targeted expansion in regulated markets (US, EU, Brazil) – new & existing molecules
4 commercial launches of new molecules each year beginning FY27
Focus on a mix of: a) High-value or b) Large-volume + sizable market share molecules
Target patented molecules supply chain beyond FY29-30
Deploy backward integration selectively to optimize inputs cost & improve contribution margins
Product Selection Framework
Mid-Size Molecules
Small-to-Mid size molecules + Aim double- digit market share
Client Fit Favour APIs requested by current marquee clientele
Margin Profile Aim for ~50% gross margins
Investor Presentation | Wanbury Limited
20
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S
API: Safety First Culture
Investor Presentation | Wanbury Limited
21
Re-Building Business
Brand Portfolio
Strategy & Way Forward
23
24
25
Business Profile: Formulations
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S
Formulations: Re-Building Business
Overview •
Formulations business journey commenced in 1995 with the acquisition of Wander Ltd, formerly a division of Sandoz
• Current portfolio is focused on
therapeutics such as anti-cold & cough, anti-infective, anti- inflammatory, analgesic, antipyretic, orthopaedic and constipation medications, as well as protein supplements, multivitamins, and multimineral supplements
• Operating through a fully outsourced manufacturing model, enabling enhanced scalability and flexibility
•
Strategic emphasis remains on building strong brands & distribution channels, driven by a dedicated business excellence team
10+ Brands
300+ Field Force
17 C&F Agents
100% Acute Therapy
30,000+ Doctors Engaged
1,800+ Distributors
Formulations - Revenue & Share
13%
11% 12%
10%
9%
43
64
63
62
71
FY21 FY22 FY23 FY24 FY25
Sales
Revenue Share
Revenue Mix – Top Brands
36%
43%
8%
13%
#1 Brand
#2 Brand
#3 Brand
Others
Investor Presentation | Wanbury Limited
23
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S
Formulations: Brand Portfolio
Top brands
Anti Cold & Cough
Pain & Inflammation, Muscular Spasm
Antacids & Anti-ulcerants
Herbal Laxative
Protein Supplement
Calcium Supplement - Osteoporosis & Bone Health
Nutritional Supplement
Multivitamin Supplement
Investor Presentation | Wanbury Limited
24
0 3 / B U S I N ES S P R O F I L E: F O R M U L A T I O N S
Formulations: Strategy & Way Forward
Operational Objectives
Strategic Way Forward
1
2
3
Latest brand launch (FY25) C RED (Iron Supplement)
Leverage 3+ decades of heritage to re-build a scalable branded formulations franchise
Upcoming therapeutic launches Paediatrics, Dermatology: Better right-to-win through existing brand equity with Paediatricians
Transition portfolio from acute therapeutics towards speciality and chronic segments through new launches
Cardiology & Diabetes: Launching chronic & speciality products to improve productivity & add portfolio diversity
Geographical expansion in newer attractive markets
Speciality Segments: Building presence across GYN/PED/CP/ORTHO/SUR segments
Planned geographic expansion Expansion into newer attractive regions
Increasing field force for existing regions
Achieve profitability break-even in FY26 through better scale & cost-management efforts
Deliver sustainable profitability FY27 onwards, through: Scaling top brands, launching new therapies, increasing front-line doctor engagement
Investor Presentation | Wanbury Limited
25
Performance Highlights
Business Vertical Performance
P&L Snapshot
Management Commentary
27
28
29
30
Q2 & H1FY26 Earnings Update
0 4 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E
Q2 & H1FY26 Performance Highlights
Revenue (in ₹ Crore)
161
163
160
-0.7%
QOQ GROWTH
EBITDA (in %)
20%
QQQ GROWTH
PAT (in ₹ Crore)
89%
QOQ GROWTH
323
292
10.6%
YOY GROWTH
Q2FY25
Q1FY26
Q2FY26
H1FY25
H1FY26
22
25
26
51
34
51%
YOY GROWTH
Q2FY25
Q1FY26
Q2FY26
H1FY25
H1FY26
13
15
8
29
217%
YOY GROWTH
9
Q2FY25
Q1FY26
Q2FY26
H1FY25
H1FY26
Investor Presentation | Wanbury Limited
27
0 4 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E
Business Vertical Performance
API - Revenue (in ₹ Crore)
141
142
135
-5.0%
QOQ GROWTH
277
256
8.2%
YOY GROWTH
Q2FY25
Q1FY26
Q2FY26
H1FY25
H1FY26
Formulations - Revenue (in ₹ Crore)
19
18
22
22.2%
QOQ GROWTH
40
34
17.6%
YOY GROWTH
Q2FY25
Q1FY26
Q2FY26
H1FY25
H1FY26
Investor Presentation | Wanbury Limited
28
0 4 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E
Q2 & H1FY25 P&L Snapshot
PARTICULARS (in ₹ Crore)
Q2FY25
Q1FY26
Q2FY26
YOY Change QOQ Change
H1FY25
H1FY26
YOY Change
Revenue from Operations
161.19
163.18
160.06
Other Income
COGS
Gross Profit
Gross Margin (%)
Operating Expenses
EBITDA
EBITDA Margin (%)
Finance Cost
Depreciation
Profit before Tax
Profit after Tax
PAT Margins (%)
Basic EPS (in ₹)
Investor Presentation | Wanbury Limited
1.63
82.02
80.80
0.35
75.35
88.18
0.20
67.06
93.20
50.13%
54.04%
58.23%
59.16
21.64
63.40
24.79
67.22
25.98
13.42%
15.19%
16.23%
10.15
3.32
8.17
8.02
4.98%
2.44
7.54
3.64
13.61
13.49
8.27%
4.12
7.12
3.70
15.16
15.18
9.48%
4.58
-1%
-88%
-18%
15%
16%
14%
20%
21%
-30%
11%
86%
89%
91%
88%
-2%
-42.86%
-11.00%
5.69%
7.75%
6.03%
4.81%
6.85%
-5.57%
1.65%
11.41%
12.53%
14.72%
11.17%
292.3
2.58
148.27
146.61
323.2
0.55
142.40
181.35
50.16%
56.11%
113.04
33.56
130.62
50.77
11.48%
15.71%
14.66
7.34
28.77
28.67
17.74
6.61
9.21
9.06
3.10%
2.76
10.57%
-78.68%
-3.96%
23.70%
11.87%
15.55%
51.26%
36.80%
-17.36%
11.04%
212.22%
216.45%
8.87%
186.19%
8.70
215.22%
29
0 1 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E
Management Commentary
Q2 continues to be stronger with EBITDA achievement of ₹ 26.0 (16.2%) crore as compared to ₹21.6 (13.3%) crore in Q2 FY25, registering a growth of 20% over previous quarter, overall improvement of 292 bps of revenues. Further, achieved PAT of ₹ 15.2 crore as compared to ₹ 8.0 crore in Q2 FY25, registering a robust growth of approx. 90 % led by cost efficiencies, improved Product yield & lower finance cost.
This improvement was driven by several technical initiatives including enhanced product yields and higher solvent recoveries. Additionally, contributed by procurement efficiencies—such as improved negotiations through auction-based sourcing for large-volume raw materials and longer period suppliers’ contracts for KSM.
The Company’s Formulations business turned EBITDA positive supported by the successful launch of the new brand (C-red-advanced liposomal iron supplement), overall improved field productivity across Brands through targeted training of the sales force and various brand promotion activities.
The recent implementation of the SAP S/4HANA Private Cloud under the Rise with SAP initiative marks a significant milestone in our digital transformation journey. This will enable greater agility, operational transparency, and data-driven decision-makin across the organization.
With our CAPEX plan on its way for introduction of new products, we remain committed to sustainable growth, increasing capacities, sustaining operational efficiencies and maintaining the highest standards of quality and compliance. Our efforts are aimed at strengthening Wanbury’s position as a trusted global pharmaceutical partner while driving long-term value for all stakeholders.
Mr. Mohan Kumar Rayana Promoter & Whole Time Director
Investor Presentation | Wanbury Limited
30
Key Performance Indicators
5Y P&L Snapshot
5Y Balance Sheet Snapshot
5Y Cash Flow Snapshot
Capital Markets Overview
32
33
34
35
36
Financial Profile
0 5 / F I NA N C I A L P R O F I L E 0 1 / Q 2 & H 1F Y 2 6 EA R NI N G S U P D AT E
Key Performance Indicators
Revenue from Operations
(in ₹ Crore)
Gross Profit & Gross Margins
(in ₹ Crore & in %)
EBITDA & EBITDA Margins
(in ₹ Crore & in %)
PAT & PAT Margins
(in ₹ Crore & in %)
575.65
599.51
511.19
499.65
700. 00
600. 00
500. 00
400. 00
300. 00
200. 00
100. 00
0.00
Gross Profit
Gross Margin
EBITDA
EBITDA Margins
PAT
PAT Margins
323.20
350
300
250
200
150
100
50
0
48
51
56
42
39
212.42
197.12
276.01
308.53 181.35
60
50
40
30
20
10
0
90
80
70
60
50
40
30
20
10
0
16
13
13
7
5
36.84
24.09
72.99
79.81
50.77
18
16
14
12
10
8
6
4
2
0
100. 00
80. 00
60. 00
40. 00
20. 00
0.00
-20.00
16
9
5
5
81.47
30.40
30.53
28.67
-2
-10.40
18
16
14
12
10
8
6
4
2
0
-2
-4
FY22
FY23
FY24
FY25 H1 FY26
FY22
FY23
FY24
FY25 H1 FY26
FY22
FY23
FY24
FY25 H1 FY26
FY22
FY23
FY24
FY25 H1 FY26
Working Capital Days
(in Days)
ROCE
(in %)
ROE
(in %)
50.04
19.34
60
40
20
0
-20
-40
-60
-80
-100
-17.47
-68.47
-79.27
138
130
160
140
120
100
80
60
40
20
0
46
28
32
109
52
53
120
100
80
60
40
20
0
0
FY22
FY23
FY24
FY25 H1 FY26
FY22
FY23
FY24
FY25 H1 FY26
FY23
FY24
FY25
H1 FY26
Investor Presentation | Wanbury Limited
32
0 5 / F I NA N C I A L P R O F I L E
5Y P&L Snapshot
PARTICULARS (in ₹ Crore)
FY21
FY22
FY23
FY24
FY25
H1 FY26
Revenue from Operations
Other Income
COGS
Gross Profit
Gross Margin (%)
Operating Expenses
EBITDA
EBITDA Margin (%)
Finance Cost
Depreciation
Exceptional Item
Profit before Tax
Profit after Tax
PAT Margins (%)
Basic EPS (in ₹)
Investor Presentation | Wanbury Limited
392.5
2.4
221.3
173.6
44%
153.2
20.42
5%
23.07
9.75
-
-12.4
-12.61
-3%
-5.04
511.2
1.51
300.3
212.4
42%
175.6
36.84
7%
20.61
11.45
76.37
81.13
81.47
16%
25.29
499.7
0.91
303.4
197.1
39%
173
24.09
5%
21.4
12.38
-0.6
-9.69
-10.4
-2%
-3.18
575.7
2.99
302.6
276
48%
203
72.99
13%
29.18
13.03
599.51
3.49
294.47
308.53
51%
228.73
79.81
13%
36.95
13.31
-
-
30.78
30.4
5%
9.29
29.55
30.53
5%
9.32
323.2
0.55
142.4
181.35
56%
130.62
50.77
16%
14.66
7.34
-
28.77
28.67
9%
8.7
33
0 5 / F I NA N C I A L P R O F I L E
5Y Balance Sheet Snapshot
PARTICULARS (in ₹ Crore)
FY21
FY22
FY23
FY24
FY25
H1 FY26
Equity Share Capital Equity Share Capital Other Equity
Non-Current Liabilities Long Term Borrowings Others Current Liabilities Short Term Borrowings Trade Payables Advances from customers Others Total Equity and Liabilities
Non-Current Assets Tangible Assets CWIP Others Current Assets Inventories Trade Receivables Current Investments Cash & Bank Balances Others Total Assets
Investor Presentation | Wanbury Limited
25.01 -155.7
71.99 18.07
88.43 133.27 3.32 103.18 287.6
158.11 11.01 22.53
24.85 34.47 - 11.66 24.97 287.6
32.67 -30.48
- 16.2
67.02 191.1 14.92 59.54 351
148.7 2.35 30.24
49.73 62.8 - 25.27 31.9 351
32.7 -39.96
-
16.31
64.14 148.2 9.27 71.58 302.2
151.5 1.61 28.59
21.99 68.98 - 3.89 25.68 302.2
32.74 -4.8
82 19.45
27.27 162.8 2.78 20.93 343.1
149 3 32.19
36.02 89.44 - 5.9 27.55 343.1
32.77 26.5
160.29 19.74
12.94 138.46 2.97 20.25 413.92
189.69 5.38 25.4
37.68 114.16 - 12.83 28.78 413.92
34.88 72.35
143.94 20.17
50.02 112.53 3.85 18.82 456.56
189.6 13.39 29.84
46.37 127.36 - 9.29 40.71 456.56
34
0 5 / F I NA N C I A L P R O F I L E
5Y Cash Flow Snapshot
PARTICULARS (in ₹ Crore)
Cash Flow from Operating Activities
Cash Flow from Investing Activities
FY21
16.68
8.04
FY22
37.56
0.59
FY23
FY24
FY25
H1 FY26
19.8
-8.84
4.02
26.1
-5.66
-16.62
-51.17
-15.27
Cash Flow from Financing Activities
-17.38
-25.62
-31.99
14.55
25.73
21.34
Net Cash Flows
Cash at the Beginning of Year
Cash at the End of Year
7.34
2.62
9.96
12.53
-21.03
9.96
22.49
22.49
1.46
1.95
1.45
3.4
0.66
3.4
4.06
0.42
4.06
4.48
Investor Presentation | Wanbury Limited
35
0 5 / F I NA N C I A L P R O F I L E
Capital Markets Overview
Shareholding Pattern
(%)
0.81
56.10
Current Market Price
43.09
52 Week High/Low
Promoters
Public
FIIs + DIIs
Market Capitalization
No. of Shares Outstanding
NSE
BSE
Shareholding data as of 30th September 2025
Market price data as of 21st November 2025
Investor Presentation | Wanbury Limited
₹230
₹330 / ₹154
₹800 Crore
3.49 Crore
WANBURY
524212
36
Get in Touch
This document which has been prepared by Wanbury Limited (“Wanbury” or “the Company”), has been prepared solely for information purposes. This document has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Document. This Document may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Document is expressly excluded.
Certain matters discussed in this Document may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world- wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Document. The Company assumes no obligation to update any forward-looking information contained in this Document. Any forward-looking statements and projections made by third parties included in this Document are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
Investor Presentation | NOVEMBER 2025
Wanbury Limited Vinod Verma Chief Financial Officer
investor@wanbury.com investorrelations@wanbury.com
TIL Advisors Private Limited Sayam Pokharna Investor Relations Advisor
sayam@theinvestmentlab.in